Rubio JM, Taipale H, Tanskanen A, et al. - Often, long-term treatment with antipsychotic medication is required for schizophrenia. Researchers herein followed up a national cohort of first-episode psychosis patients in Finland for up to 18 years with the aim to investigate the continuity of antipsychotic treatment over the course of illness in schizophrenia, as well as determine the factors linked with the interruption of treatment. The median number of continuous treatment episodes was 6 with a median period of 11.4 months among 3,343 participants followed up for a mean of 8 years. A progressive decrease in the risk of discontinuation was observed over successive treatment episodes. Likelihood to interrupt treatment was 67% less among individuals in correlation with receiving long-acting injectable than oral antipsychotics. Recurrent cycles of interruptions and reintroductions of antipsychotic medication are often observed in treatment for schizophrenia over the long term, which is typically not recommended by management guidelines. Findings support greater utilization of long-acting injectable formulations earlier in the course of illness that may allow the continuity of antipsychotic treatment in schizophrenia.